Long lasting changes of motor function in MPTP-induced unilateral cynomolgus monkeys model

doi:10.3969/j.issn.1006-7795.2018.02.013

Abstract

Abstract: Objective To establish long lasting changes of motor function in MPTP-induced non-human primate models for investigating neuroprotective therapy. We try to study the dynamic changes of motor function of MPTP-induced unilateral Parkinson's disease model in cynomolgus monkeys. Methods Total 5 healthy male cynomolgus monkeys (6~7 years old) were injected MPTP into the left internal carotid artery. The motor behavior changes were evaluated by clinical rating score and physical activity monitoring before and after MPTP injection at 3 and 6 months, 1, 3, and 6 years. Results The clinical rating score was significantly increased and reached the peak (14.65±8.41) at 3 months and partially recovered at 6 months (8.10±2.01, P=0.006), but maintained stable to 6 years after MPTP injection. The 24 h physical activity was significantly decreased and reached the peak at 3 months (16 597.79±12 488.87, P=0.014), 6 months (29 278.02±12 264.66, P=0.016) but recovered to the baseline level (50 084.20±30 170.89) after 1 year. Conclusion The results suggest that the motor deficit assessed by clinical rating score of MPTP-induced unilateral Parkinson's disease model in cynomolgus monkeys can last up to 6 years.

Key words: Parkinson's disease, cynomolgus monkeys, motor behavior, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)

CLC Number:

R742.5

Luo Binbin, Hu Yasong, Yue Feng, Chen Biao. Long lasting changes of motor function in MPTP-induced unilateral cynomolgus monkeys model[J]. Journal of Capital Medical University, 2018, 39(2): 217-222.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.02.013

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I2/217

References

[1] Ponsford J P. Therapies for dopaminergic-induced dyskinesias in parkinson disease[J]. Ann Neurol, 2011, 70(4):667.
[2] Zhang J, Stanton D M, Nguyen X V, et al. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits[J]. Neuroscience, 2005, 135(3):829-838.
[3] Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease[J]. J Neurol, 2010, 257(7):1073-1082.
[4] de Lau L M, Breteler M M. Epidemiology of Parkinson's disease[J]. Lancet Neurol, 2006, 5(6):525-535.
[5] Choi D Y, Zhang J, Bing G. Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats[J]. Neurobiol Aging, 2010, 31(9):1649-1653.
[6] 户乃丽, 刘玉军, 徐群渊,等. 黑质内炎症反应对恒河猴多巴胺能神经元的毒性作用[J]. 解剖学报, 2009, 40(5):732-736.
[7] Zenzola A, Masi G, De Mari M, et al. Fatigue in Parkinson's disease[J]. Neurol Sci, 2003, 24(3):225-226.
[8] Zhang J R, Chen J, Yang Z J, et al. Rapid eye movement sleep behavior disorder symptoms correlate with domains of cognitive impairment in parkinson's disease[J]. Chin Med J(Engl), 2016, 129(4):379-385.
[9] Pessoa Rocha N, Reis H J, Vanden Berghe P, et al. Depression and cognitive impairment in parkinson's disease:a role for inflammation and immunomodulation?[J]. Neuroimmunomodulation, 2014, 21(2-3):88-94.
[10] Sateia M J. International classification of sleep disorders-third edition:highlights and modifications[J]. Chest, 2014, 146(5):1387-1394.
[11] Jingzhong Z, Hui Y, Deyi D, et al. Long-term therapeutic effects on parkinsonian rats of intrastriatal co-grafts with genetically engineered fibroblasts expressing tyrosine hydroxylase and glial cell line-derived neurotrophic factor[J]. Int J Neurosci, 2005, 115(6):769-779.
[12] Sulzer D, Surmeier D J. Neuronal vulnerability, pathogenesis, and parkinson's disease[J]. Mov Disord, 2013, 28(1):715-724.
[13] Lorigados L,Alvarez P, Pavón N, et al. NGF in experimental models of Parkinson disease[J]. Mol Chem Neuropathol, 1996, 28(1-3):225-228.
[14] Kurlan R, Kim M H, Gash D M. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys:assessment with a new rating scale for monkey parkinsonism[J]. Mov Disord, 1991, 6(2):111-118.
[15] Domino E F, Ni L. Trihexyphenidyl potentiation of l-DOPA:reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys[J]. Exp Neurol, 1998, 152(2):238-242.
[16] Emborg-Knott M E, Domino E F. MPTP-induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose[J]. Exp Neurol, 1998, 152(2):214-220.
[17] Yagi S, Yoshikawa E, Futatsubashi M, et al. Progression from unilateral to bilateral parkinsonism in early Parkinson disease:implication of mesocortical dopamine dysfunction by PET[J]. J Nucl Med, 2010, 51(8):1250-1257.
[18] Wood H. Parkinson disease:18F-DTBZ PET tracks dopaminergic degeneration in patients with Parkinson disease[J]. Nat Rev Neurol, 2014, 10(6):305.
[19] Ghaemi M, Raethjen J, Hilker R, et al. Monosymptomatic resting tremor and Parkinson's disease:a multitracer positron emission tomographic study[J]. Mov Disord, 2002, 17(4):782-788.
[20] Chen M, Wang T, Yue F, et al. Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral alpha-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys[J]. Neuroscience, 2015, 286:383-392.
[21] Hawkes C H, Del Tredici K, Braak H. Parkinson's disease:a dual-hit hypothesis[J]. Neuropathol Appl Neurobiol, 2007, 33(6):599-614.
[22] Yue F, Zeng S, Tang R, et al. MPTP induces systemic parkinsonism in middle-aged cynomolgus monkeys:clinical evolution and outcomes[J]. Neurosci Bull, 2017, 33(1):17-27.
[23] Sonni I, Fazio P, Schain M, et al. Optimal acquisition time window and simplified quantification of dopamine transporter availability using 18F-FE-PE2I in ealthy controls and parkinson disease patients[J]. J Nucl Med, 2016, 57(10):1529-1534.
[24] Emborg M E, Shin P, Roitberg B, et al. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys[J]. Exp Neurol, 2001, 168(1):171-182.
[25] Blini E, Romeo Z, Spironelli C, et al. Multi-tasking uncovers right spatial neglect and extinction in chronic left-hemisphere stroke patients[J]. Neuropsychologia, 2016, 92:147-157.
[26] Bhidayasiri R, Trenkwalder C. Getting a good night sleep? The importance of recognizing and treating nocturnal hypokinesia in Parkinson's disease[J]. Parkinsonism Relat Disord, 2018[Epub ahead of print].
[27] Louter M, Maetzler W, Prinzen J, et al. Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls[J]. J Neurol Neurosurgery Psychiatry, 2015, 86(1):32-37.
[28] Nero H, Benka Wallén M, Franzen E, et al. Objectively assessed physical activity and its association with balance, physical function and dyskinesia in parkinson's disease[J]. J Parkinsons Dis, 2016, 6(4):833-840.
[29] Jan C, Pessiglione M, Tremblay L, et al. Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys[J]. Eur J Neurosci, 2003, 18(7):2082-2086.
[30] Zhang Z, Weeks R, Grondin R, et al. Similarities and differences in cognitive deficits and responsiveness to L-Dopa between aged and MPTP-treated cynomolgus monkeys tested on the same tasks[J]. J Gerontol Geriatr Res, 2014, 3:5.